(NASDAQ: AMRN) Amarin's forecast annual revenue growth rate of -1.47% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Amarin's revenue in 2025 is $214,112,000.On average, 3 Wall Street analysts forecast AMRN's revenue for 2025 to be $72,380,531,641, with the lowest AMRN revenue forecast at $60,257,404,484, and the highest AMRN revenue forecast at $87,768,740,427. On average, 3 Wall Street analysts forecast AMRN's revenue for 2026 to be $76,832,539,189, with the lowest AMRN revenue forecast at $64,108,908,688, and the highest AMRN revenue forecast at $96,573,361,866.
In 2027, AMRN is forecast to generate $85,521,201,361 in revenue, with the lowest revenue forecast at $77,816,950,532 and the highest revenue forecast at $98,275,478,240.